home / stock / cgtx / cgtx news

CGTX News and Press, Cognition Therapeutics Inc. From 12/15/22

Stock Information
Company Name: Cognition Therapeutics Inc.
Stock Symbol: CGTX
Market: NASDAQ
Website: cogrx.com
Menu
CGTX CGTX Quote CGTX Short CGTX News CGTX Articles CGTX Message Board
Get CGTX Alerts

News, Short Squeeze, Breakout and More Instantly...
CGTX - First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

PURCHASE, N.Y., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced that the Phase 2 SHINE clinical trial of CT1812, an experimental oral, once-daily capsule in development for mild-to-moderate Alzheim...
CGTX - Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geogr...

CGTX - Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

PURCHASE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing SHIMMER clinical trial of CT1812 will be presented at...

CGTX - Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has introduced a new podcast/webinar series named “Conversations,” that will feature virtual fireside chats with neur...
CGTX - Cognition Therapeutics Announces Closing of Public Offering

PURCHASE, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public...

CGTX - Cognition Therapeutics GAAP EPS of -$0.29 beats by $0.09

Cognition Therapeutics press release ( NASDAQ: CGTX ): Q3 GAAP EPS of -$0.29 beats by $0.09 . Cash and cash equivalents at September 30, 2022 were approximately $46.6 million. For further details see: Cognition Therapeutics GAAP EPS of -$0.29 beats by $0.09 ...

CGTX - Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

- SHINE Alzheimer’s Trial Expands to European Sites - - SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete - - Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active - PURCHASE, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, ...
CGTX - Cognition Therapeutics Announces Pricing of Public Offering

PURCHASE, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company” or “Cognition”) announced today the pricing of the public offering of 5,000,000 shares of its common stock, at a public offering price of $1.20 per share, for g...

CGTX - Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

PURCHASE, N.Y., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Lewy Body Dementia (LBD) patients are actively being recruited by Cognition Therapeutics, Inc. (Nasdaq: CGTX) and its clinical partners for the SHIMMER Phase 2 trial of their CT1812 oral drug therapy at 17 study sites across the country...

CGTX - Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operatio...
Previous 10 Next 10